Skip to main content
Ovoca Bio Plc logo

Ovoca Bio Plc — Investor Relations & Filings

Ticker · OVXA ISIN · IE00B4XVDC01 LEI · 213800ST2AK5XQ1O5207 IR Manufacturing
Open in API
Filings indexed 99 across all filing types
Latest filing 2021-02-16 AGM Information
Country IE Ireland
Listing IR OVXA

About Ovoca Bio Plc

https://ovocabio.com/

Ovoca Bio is a clinical-stage biopharmaceutical company focused on developing novel treatments for women's health. Its lead product candidate is Orenetide, a treatment for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack of sexual desire and representing a significant area of high unmet medical need. The company is advancing Orenetide through clinical development for major global markets and has filed for marketing approval in the US and Europe. Ovoca Bio's strategy includes leveraging its patent portfolio and considering licensing or collaboration opportunities to accelerate the availability of its product candidates to patients.

Recent filings

Filing Released Lang Actions
Result of EGM
AGM Information Classification · 99% confidence The document is an official announcement disseminated via RNS (RNS Number: 2826P) detailing the 'Result of Extraordinary General Meeting'. It explicitly lists the resolutions proposed and the detailed poll results (Votes for, Votes Against, etc.). This content directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements'. Although it relates to a general meeting, the core content is the voting outcome, making DVA the most precise classification over AGM-R (which is for presentations/materials) or RPA/RNS (which are for announcements of reports, not the results themselves).
2021-02-16 English
First Patient Enrolled in Phase II Study - BP-101
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 2502N' and contains standard regulatory boilerplate language at the end, including references to RNS, the London Stock Exchange, and the Financial Conduct Authority. The content announces a specific corporate event: the enrollment of the first patient in a Phase II clinical trial for a drug (BP-101) for HSDD. This type of announcement, which is a material, non-financial update disseminated via a regulatory news service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K, ER, IR) or a specific corporate action like a dividend or management change. Given the source (RNS Number) and the nature of the announcement (clinical trial update), RNS is the most appropriate classification.
2021-01-29 English
Notice of EGM
Regulatory Filings Classification · 98% confidence The document explicitly announces a 'Notice of Extraordinary General Meeting' (EGM) to be held on February 16, 2021. It details the purpose of the meeting (shareholder approval for migration of shares and changes to Articles of Association) and mentions that the 'Circular, which includes the notice of the EGM... will be posted to shareholders today.' This document is an announcement related to a shareholder meeting and the associated materials (Circular/Proxy). This aligns best with the definition of materials shared during a general meeting, which points towards AGM-R, although the meeting is an EGM, the category AGM-R covers general meeting materials. Since it is a formal notice and announcement regarding a shareholder meeting, AGM-R is the most appropriate fit among the specific options, as opposed to a general regulatory filing (RNS) or a proxy solicitation document (PSI), which usually solicits votes for an upcoming AGM/EGM.
2021-01-25 English
Re-Filing of Marketing Authorisation Application
Regulatory Filings Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content announces a specific corporate action: the resubmission of a Marketing Authorisation Application (MA) for a drug (BP-101) to the Russian Ministry of Health. This is a material, time-sensitive announcement to the market, typical of regulatory news services. Since it is a general regulatory announcement that doesn't fit perfectly into specific categories like ER, 10-K, or DIV, the most appropriate classification is the general regulatory filing category, RNS. The document length (4405 chars) is moderate, but the content is purely an announcement of an event/filing, not the full report itself.
2021-01-05 English
Result of AGM
AGM Information Classification · 99% confidence The document explicitly states it is announcing the 'Result of Annual General Meeting' held on December 17, 2020, and confirms that 'each of the resolutions proposed... were duly passed by shareholders.' This directly relates to the outcome of a shareholder vote following an AGM. Therefore, the most appropriate classification is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, DVA is more specific for the results than AGM-R (which is for presentations/materials). The document is short and is an announcement of results, not the full AGM presentation.
2020-12-17 English
Notice of AGM
AGM Information Classification · 99% confidence The document explicitly states 'Notice of Annual General Meeting' and details the date, time, and location of the '2020 Annual General Meeting ("AGM")'. It also mentions that the 'Notice of AGM' has been published and is available to shareholders. This content directly relates to the meeting itself, not the voting results (DVA) or the proxy solicitation materials (PSI), but rather the announcement and logistics surrounding the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (4628 chars) is substantial enough that it is not just a brief announcement of a report (RPA/RNS), but the core notice itself.
2020-11-27 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.